Neoadjuvant atezolizumab together with chemotherapy is safe and has promising activity in patients with gastric and gastro-oesophageal junction adenocarcinoma

Findings of the recently published PANDA phase II study have shown that a "combination of neoadjuvant atezolizumab plus chemotherapy led to a major pathologic response in 70% and a pathologic complete response in 45% of patients with previously untreated resectable gastric and gastro-oesophageal junction cancer."  In addition, 13 of 14 responses did not exhibit disease recurrence after 47 months.   In addition, the PANDA study has shown that atezolizumab monotherapy leads to prominent changes in the tumour microenvironment.  

To learn more about the PANDA study, click here. 

Source mentioned: 

Verschoor YL, van de Haar J, van den Berg J, et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial. Nature Medicine; Published online 8 January 2024. DOI: https://doi.org/10.1038/s41591-023-02758-x